4D Molecular Therapeutics, Inc. Balance Sheet
FDMT|6 years of annual SEC 10-K data (FY2020-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 6 fiscal years. All figures from audited SEC 10-K filings.
4D Molecular Therapeutics, Inc. had $567M in total assets and $511M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.26 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $60.2M | $149.3M | $249.1M | $52.4M | $153.0M | $276.7M |
| Accounts Receivable | - | - | - | - | $47.0K | $1.5M |
| Current Assets | $413.1M | $434.9M | $296.6M | $220.5M | $256.3M | $282.7M |
| PP&E (Net) | $14.9M | $19.5M | $20.1M | $22.3M | $14.4M | $5.1M |
| Total Assets | $566.7M | $560.4M | $339.9M | $261.8M | $353.5M | $288.3M |
| Current Liabilities | $44.0M | $29.1M | $19.0M | $15.7M | $16.3M | $16.7M |
| Shareholders' Equity | $510.6M | $307.8M | $231.3M | $319.1M | $256.4M | -$73.0M |